Somaform's Interface Review Drags On, and the Waiting List Grows

The regulatory review of Somaform Augmetics' newest neural-interface line entered its third month this week with no verdict and a queue that lengthens by the day. Regulators opened the look last summer after a cluster of adaptation complaints — nothing catastrophic, the company stresses, but enough to freeze new implantations of the line pending a full safety read. What began as routine caution has become, in practice, a rationing mechanism: clinics that would be fitting the interface are instead maintaining a waiting list, and the list now sorts, inevitably, by who can wait and who cannot. Founder Julian Morrow, who built the company on the promise that augmentation should widen rather than narrow, called the delay "responsible and also a quiet injustice — every month we pause, the implant becomes a thing for the patient people, which means the comfortable ones." Regulators counter that a rushed clearance would be the real injustice. Both are describing the same waiting room, filling by the week, where the oldest question in augmentation — who gets to be enhanced — is being answered by a calendar.